Meeting
2022 ASCO Annual Meeting
Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center.
Authors
Jeffrey Aldrich
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Jeffrey Aldrich , Jeffrey M. Switchenko , Kevin Kalinsky , Manali A. Bhave
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1074)
DOI
10.1200/JCO.2022.40.16_suppl.1074
Abstract #
1074
Poster Bd #
452
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2023 ASCO Genitourinary Cancers Symposium
Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
First Author: Ronac Mamtani
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod